Lilly & CO Eli is > 10% Shareholder of Sigilon Therapeutics, Inc.. Currently has a direct ownership of 100 shares of SGTX, which is worth approximately $0. The most recent transaction as insider was on Aug 11, 2023, when has been sold 1,718,493 shares (Common Stock) at a price of $14.92 per share, resulting in proceeds of $25,639,915. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 100
0% 3M change
0% 12M change
Total Value Held $0

LILLY & Co ELI Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 11 2023
BUY
Open market or private purchase
$25,639,915 $14.92 p/Share
1,718,493 Added 99.99%
100 Common Stock
Dec 08 2020
BUY
Open market or private purchase
$5,400,000 $18.0 p/Share
300,000 Added 9.85%
2,744,443 Common Stock
Dec 08 2020
BUY
Conversion of derivative security
-
2,444,443 Added 50.0%
2,444,443 Common Stock

Also insider at

ELAN
Elanco Animal Health Inc Healthcare
RNA
Avidity Biosciences, Inc. Healthcare
ZYME
Zymeworks Inc. Healthcare
LPTX
LEAP THERAPEUTICS, INC. Healthcare
CLCD
CoLucid Pharmaceuticals, Inc.
L&C

Lilly & CO Eli

> 10% Shareholder
Indianapolis, IN

Track Institutional and Insider Activities on SGTX

Follow Sigilon Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SGTX shares.

Notify only if

Insider Trading

Get notified when an Sigilon Therapeutics, Inc. insider buys or sells SGTX shares.

Notify only if

News

Receive news related to Sigilon Therapeutics, Inc.

Track Activities on SGTX